Shopping Cart
Remove All
Your shopping cart is currently empty
Clivatuzumab tetraxetan (IMMU107), a humanized anti-MUC1 monoclonal antibody, exhibits anti-tumor activity and holds potential for research in metastatic pancreatic cancer [1] [2].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Clivatuzumab tetraxetan (IMMU107), a humanized anti-MUC1 monoclonal antibody, exhibits anti-tumor activity and holds potential for research in metastatic pancreatic cancer [1] [2]. |
| In vivo | Clivatuzumab tetraxetan (50, 100 µg; i.v.; once) effectively reduced tumor volume in a dose-dependent manner and extended the median survival of nude mice with Capan-1 tumors to 13 weeks. [2] Animal Model: Nude mice (Capan-1 tumors) [2] Dosage: 50, 100 µg Administration: I.v.; once Result: Significantly decreased tumor volume in a dose-dependent manner and increased the median survival to 13 weeks. |
| Synonyms | IMMU107 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 1462876-11-4 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.